Tandem Diabetes

$127.40 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Tandem Diabetes

Tandem Diabetes Care, Inc. is a medical device company engaged in the designing, developing and commercialization of products for people with insulin-dependent diabetes. The Company’s manufacturing, sales and support activities principally focus on its flagship pump platform, the t:slim X2 Insulin Delivery System (t:slim X2), and its product offerings. The t:slim X2 is based on its technology platform and is capable of remote feature updates and is designed to display continuous glucose monitoring (CGM) sensor information directly on the pump home screen. Its products also include Basal-IQ technology and Control-IQ technology. The Basal-IQ technology is a predictive low glucose suspend feature that is designed to temporarily suspend insulin delivery to help reduce the frequency and duration of hypoglycemic events. The Control-IQ technology is a hybrid-closed loop feature, designed to help increase a user's time in targeted glycemic range.

Stock Analysis

last close $127.37
1-mo return 4.3%
3-mo return 26.1%
avg daily vol. 546.72T
52-week high 136.1
52-week low 76.19
market cap. $7.9B
forward pe 274
annual div. -
roe 2.1%
ltg forecast -
dividend yield -
annual rev. $605M
inst own. 96.6%
baraka

Subscribe now for daily local and international financial news

Subscribe